The panelist discusses how incorporating chemotherapy into combination treatments for metastatic prostate cancer presents challenges such as increased resource requirements, the need for ...

Zaorsky discusses his team's ASTRO 2024 abstract showing clear benefit of radiotherapy and ablation in reduced kidney effects in patients with RCC. Stereotactic body radiotherapy (SBRT), partial ...

Fred Saad, CQ, MD, FRCS, FCAHS, discusses how combining therapies like androgen receptor–targeted agents, androgen deprivation therapy, and docetaxel can potentially improve outcomes for metastatic ...

“At a median follow-up of 37 months, we saw that failure-free survival was statistically significant, with 2 times more events seen in the control arm," said Colin Belliveau, MD. Results of a phase 2 ...

Video content above is prompted by the following question: What are some unmet needs in prostate cancer care today, particularly regarding diagnosis, risk stratification and treatment? How can these ...

A late-breaking abstract at ASTRO 2024 shows local therapy history does not significantly affect the risk of death in patients with mCRPC receiving an ARPI. The treatment effects of first-line ...

Findings from RAPTOR suggest 5-year biochemical recurrence may be a good indication of prostate cancer cure status. Biochemical recurrence within 5 years of treating prostate cancer with radiotherapy ...

Panelists discuss how non–muscle-invasive bladder cancer (NMIBC) presents with specific symptoms and diagnostic procedures, emphasize the significant economic burden on health care systems, and ...

"We think that radiation therapy is one of the best treatment options available for kidney cancer," says Nicholas Zaorsky, MD, MS. Stereotactic body radiotherapy (SBRT) may provide the best ...

Demogeot discusses his team's GETUG 14 findings regarding early administration of ADT plus high-dose radiotherapy for intermediate to high risk prostate cancer. The data from the phase 3 GETUG trial, ...

Data from the PARTIQoL trial show no significant difference in progression-free survival, bowel function, and other patient quality-of-life measures between PBT and IMRT. Proton beam therapy (PBT) and ...

The phase 3 ENLIGHTED trial has reached the 50% patient enrollment threshold. The 50% patient enrollment threshold has been reached in the phase 3 ENLIGHTED trial (NCT04620239), exploring padeliporfin ...